A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
A Multi-center, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Yuki Prescott
- Phone Number: 919-460-9500
- Email: yprescott@arrivobio.com
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85012
- IMA Clinical Research
-
Tucson, Arizona, United States, 85704
- Noble Clinical Research
-
-
Arkansas
-
Bryant, Arkansas, United States, 72022
- SanRo Clinical Research Group
-
-
California
-
Bellflower, California, United States, 90706
- Clinical Innovations
-
Imperial, California, United States, 92251
- Sun Valley Research Center
-
Lemon Grove, California, United States, 91945
- Synergy San Diego
-
Oceanside, California, United States, 92056
- Excell Research
-
Riverside, California, United States, 92506
- CITrials
-
Torrance, California, United States, 90504
- Collaborative Neuroscience Research
-
Walnut Creek, California, United States, 94596
- Sunwise Clinical Research
-
West Covina, California, United States, 91790
- Next Level Clinical Trials
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80910
- MCB Clinical Research Centers
-
-
Florida
-
Jacksonville, Florida, United States, 32256
- Clinical Neuroscience Solutions
-
Lakeland, Florida, United States, 33803
- Accel Clinical
-
Lauderhill, Florida, United States, 33319
- Segal Trials
-
Miami Lakes, Florida, United States, 33016
- Segal Trials - Miami Lakes
-
Orlando, Florida, United States, 32801
- Clinical Neuroscience Solutions
-
Pinellas Park, Florida, United States, 33782
- DMI Research
-
-
Georgia
-
Atlanta, Georgia, United States, 30328
- Accelerated Enrollment Solutions
-
-
Idaho
-
Meridian, Idaho, United States, 83642
- Velocity Clinical Research
-
-
Illinois
-
Elgin, Illinois, United States, 60123
- Revive Research Institute
-
-
Louisiana
-
Marrero, Louisiana, United States, 70072
- Tandem Clinical Research
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02131
- Boston Clinical Trials
-
-
Michigan
-
Bloomfield Hills, Michigan, United States, 48302
- NeuroBehavioral Medicine Group
-
-
Missouri
-
Saint Charles, Missouri, United States, 63304
- Midwest Research Group
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68526
- Alivation Research
-
-
Nevada
-
Las Vegas, Nevada, United States, 89102
- IMA Clinical Research
-
Las Vegas, Nevada, United States, 89119
- Redbird Research
-
-
New Jersey
-
Cherry Hill, New Jersey, United States, 08002
- Center for Emotional Fitness
-
Marlton, New Jersey, United States, 08053
- CenExel HRI
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87109
- IMA Clinical Research
-
-
New York
-
Brooklyn, New York, United States, 11229
- Integrative Clinical Trials
-
New York, New York, United States, 10016
- Pioneer Clinical Research
-
-
North Carolina
-
Cary, North Carolina, United States, 27511
- Magnolia Clinical Research
-
Chapel Hill, North Carolina, United States, 27599
- UNC Chapel Hill
-
Charlotte, North Carolina, United States, 28211
- New Hope Clinical Research
-
-
Ohio
-
Beachwood, Ohio, United States, 44122
- Velocity Clinical Research
-
Dayton, Ohio, United States, 45417
- Midwest Clinical Research Center
-
Middleburg Heights, Ohio, United States, 44130
- North Star Medical Research
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Summit Headlands
-
-
South Carolina
-
North Charleston, South Carolina, United States, 29405
- Coastal Carolina Research Center
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
- Clinical Neuroscience Solutions
-
-
Texas
-
Austin, Texas, United States, 78737
- Donald J. Garcia, Jr, MD, PA
-
Dallas, Texas, United States, 75231
- Future Search Trials of Dallas
-
El Paso, Texas, United States, 79902
- Haracec Clinical Research
-
Richardson, Texas, United States, 75080
- Pillar Clinical Research
-
Stafford, Texas, United States, 77477
- R and H Clinical Research
-
Wichita Falls, Texas, United States, 76309
- Grayline Research Center
-
-
Washington
-
Bellevue, Washington, United States, 98007
- Northwest Clinical Research Center
-
Everett, Washington, United States, 98201
- Core Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Males and females, aged 18 to 65 years, inclusive.
- Meet DSM-5 criteria for moderate to severe MDD, as confirmed by the Mini International Neuropsychiatric Interview (MINI).
- In generally good physical health, in the opinion of the Investigator.
- Body mass index (BMI) must be ≥ 18 and ≤ 45 kg/m2.
Key Exclusion Criteria:
- Female who is pregnant, breastfeeding, or less than 6 months postpartum at screen.
- A history of or current DSM-5 diagnosis of MDD with psychotic features, any schizophrenia spectrum and other psychotic disorders, bipolar disorder, or personality disorder.
- Presence or history of any known clinically significant cardiovascular disorders including, but not limited to: coronary artery disease, heart failure, valvular heart disease, cardiomyopathies, myocardial infarction, chamber enlargement or hypertrophy, or orthostatic hypotension.
- Presence of uncontrolled hypertension, defined as consistent sitting systolic blood pressure (SBP) >160 mmHg or consistent sitting diastolic blood pressure (DBP) >95 mmHg despite present therapy.
- Screening laboratory value(s) outside the laboratory reference range that are considered to be clinically significant by the Investigator (clinical chemistry, hematology, thyroid function, and urinalysis).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: SP-624
Participants to receive two 10 mg capsules of SP-624 once daily for a total daily dose of 20 mg
|
Once daily oral administration of two capsules totaling 20 mg/day
|
|
Placebo Comparator: Placebo
Participant to receive 2 matching placebo capsules once daily
|
Once daily oral administration of two matching placebo capsules
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score.
Time Frame: Baseline to Week 4
|
The MADRS is a 10-item depression rating scale used to assess the severity of depression.
Individual items are scored on a 7-point scale (0 to 6).
The toal score is the sum of individual items, ranging from 0 to 60; where a higher score indicates more depression.
|
Baseline to Week 4
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline in the Clinical Global Impression - Severity (CGI-S) score.
Time Frame: Baseline to Weeks 1-4 and 1- and 2- Week Follow-up
|
The CGI-S is a 7-point scale to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participants who have the same diagnosis.
A score of 1 represents "normal" and 7 represents "most extremely ill".
|
Baseline to Weeks 1-4 and 1- and 2- Week Follow-up
|
|
Change from Baseline in Quick Inventory of Depressive Symptomology-Self-Report (QIDS-SR) total score.
Time Frame: Baseline to Weeks 1-4 and 1- and 2- Week Follow-up
|
The QIDS-SR is a 16-item self-reported scale where each item has a 4-point scale where 0 represents least impact scores while 3 represents greatest impact scores.
Some questions are linked.
The total score ranges from 0 to 27 where a higher score indicates more depression.
|
Baseline to Weeks 1-4 and 1- and 2- Week Follow-up
|
|
Change from Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score.
Time Frame: Baseline to Weeks 1-3 and 1- and 2- Week Follow-up
|
The MADRS is a 10-item depression rating scale used to assess the severity of depression.
Individual items are scored on a 7-point scale (0 to 6).
The toal score is the sum of individual items, ranging from 0 to 60; where a higher score indicates more depression.
|
Baseline to Weeks 1-3 and 1- and 2- Week Follow-up
|
|
Change from Baseline in 17-item-Hamilton Depression Rating Scale (HAM-D-17) total score.
Time Frame: Baseline to Weeks 2 and 4
|
The 17-item HAM-D is used to assess the severity of depression.
Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=No difficulty/absent and 4=most severe.
The total score is the sum of individual items, ranging from 0 to 52; where a higher score indicates more depression.
|
Baseline to Weeks 2 and 4
|
|
Change from Baseline in Sheehan Disability Scale (SDS) total score.
Time Frame: Baseline to Weeks 2 and 4
|
The SDS is a 3-part scale that measures the degree of disruption on work, social and family life using an 11-point scale where 0 represents "no disruption" and 10 represents "extreme disruption".
In addition to the 11-point scale, participants are asked to indicate the number of days in the past week that were "lost" and numbers of days that were "underproductive".
The results of these questions have a range from 0 to 7. A total global functioning impairment score can be utilized by summing the scores from work, social and family life scales for a value range from 0 to 30.
|
Baseline to Weeks 2 and 4
|
|
Change from Baseline in Symbol Digit Modalities Test (SDMT) score.
Time Frame: Baseline to Weeks 2 and 4
|
The SDMT is an assessment of complex scanning and visual tracking requiring elements of attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed.
The SDMT measures the time to pair abstract symbols with specific numbers.
The number of correct substitutions within 90 seconds is recorded and the total score is derived from the total number of correct responses with a minimum possible score of 0 and maximum of 110 where high scores indicate better outcome.
|
Baseline to Weeks 2 and 4
|
|
Incidence rates of treatment emergent adverse events (TEAEs), serious adverse events (SAEs), and TEAEs leading to withdrawal from study.
Time Frame: Baseline to Weeks 1-4 and 1- and 2- Week Follow up
|
Baseline to Weeks 1-4 and 1- and 2- Week Follow up
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Greg Rigdon, PhD, Sirtsei Pharmaceuticals, Inc.
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SP-624-202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.